This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Channick, R. N. Articles by Rubin, L. J. Search for Related Content PubMed PubMed Citation Articles by Channick, R. N. Articles by Rubin, L. J.

Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension

Richard N. Channick, MD^_*,_*, Horst Olschewski, MD, Werner Seeger, MD, Ted Staub, MS, Robert Voswinckel, MD and Lewis J. Rubin, MD^_*

^_* UCSD Medical Center, La Jolla, California
Medizinischen Universitaet Graz, Graz, Austria
University of Giessen, Giessen, Germany
LungRx, Satellite Beach, Florida

View larger version (15K): [in a new window]   Figure 1 Acute effects of inhaled treprostinil followed to 180 min and inhaled nitric oxide in 11 pulmonary arterial hypertension patients. PAPmean = mean pulmonary arterial pressure.

View larger version (9K): [in a new window]   Figure 2 Individual changes in 6-min walk (6MW) distance from baseline to 12 weeks. Pulmonary capillary hemangiomatosis (PCH) patient is shown and was the only subject to have a decrease in 6MW distance at week 12. * 10% change from baseline.